---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289468504.md"
description: "Purple Biotech shares are trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress."
datetime: "2026-06-11T11:17:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289468504.md)
  - [en](https://longbridge.com/en/news/289468504.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289468504.md)
generator: "portal-rs"
---

# 

Purple Biotech shares are trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress.

### Related Stocks

- [PPBT.US](https://longbridge.com/en/quote/PPBT.US.md)

## Related News & Research

- [Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress](https://longbridge.com/en/news/295224384.md)
- [Purple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform](https://longbridge.com/en/news/297782178.md)
- [ArcelorMittal announces Q3 2026 dividend of R$ 0.32 per unit](https://longbridge.com/en/news/298916587.md)
- [CenterPoint Energy declares dividend of R$ 0.83 per unit, payable Sept. 16](https://longbridge.com/en/news/298937595.md)
- [Active Biotech AB (publ) (STO:ACTI): Is Breakeven Near?](https://longbridge.com/en/news/298678959.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**